The overall aim of this project is to implement a non-invasive method of measuring quantitative regional cerebral blood flow (rCBF) on the UAB hybrid PET/MRI scanner to allow conducting such [O-15]water based scans with relative ease and safety in a large variety of important clinical and research applications. Participants will undergo imaging at baseline and after administration of a drug to increase cerebral blood flow to evaluate perfusion estimates during low and high flow states. The goal of this study is to generate data that will justify eliminating invasive arterial sampling in most [O-15]water-based PET protocols.

Start Date01 Feb 2025

Sponsor / Collaborator

The University of Alabama at Birmingham

CTRI/2024/09/074130 / Not yet recruitingPhase 2/3IIT

A comparative clinical study of Punarnava Gokshur GhanVati and Acetazolamide Tablet in the management Of Vataj Adhimantha (Ocular Hypertension). - Nil

Start Date01 Oct 2024

Sponsor / Collaborator-

NCT06521476 / Not yet recruitingPhase 2IIT

Impact of Acetazolamide on Central Sleep Apnea Patients Receiving Medication for Opioid Use Disorder

Patients with opioid use disorder treated with either methadone or buprenorphine are at risk of developing central sleep apnea (CSA) from these medications. Investigators will conduct a mechanistic trial using acetazolamide, a medicine known to improve CSA in other settings, to determine if acetazolamide can improve CSA due to medication for opioid use disorder and whether this leads to physiologic changes that might lead to reduced drug craving. Patients treated with medication for opioid use disorder and who have central sleep apnea will be randomized to treatment with acetazolamide or matching placebo for 7 days. At the end of the 7 days, they will undergo an overnight sleep study to assess the impact on breathing during sleep as well as sleep quality. In addition, measures of sympathetic tone, anxiety, arousal, cognition, and drug craving will be measured to determine if treatment of CSA with acetazolamide can produce physiologic changes that might contribute to improved health.

Start Date01 Oct 2024

Sponsor / Collaborator

University of Pittsburgh

[+1]

100 Clinical Results associated with Acetazolamide

100 Translational Medicine associated with Acetazolamide

100 Patents (Medical) associated with Acetazolamide

7,711

Literatures (Medical) associated with Acetazolamide

01 Jan 2025·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Ocular pharmacokinetics of acetazolamide from intravitreal implants by high-performance liquid chromatography coupled to tandem mass spectrometry

Article

Author: Castro, Matheus Augusto de ; Ribeiro, Marcela Coelho Silva ; Júnior, Armando da Silva-Cunha ; Gonçalves, José Eduardo ; Fialho, Sílvia Ligório ; Reis da Silva, Pedro Henrique ; Pianetti, Gérson Antônio ; Fernandes, Christian ; Ferreira, Eduarda Diniz

Glaucoma, a leading cause of irreversible blindness, affects about 70 million people globally. Its treatment focuses on reducing intraocular pressure. Acetazolamide, a potent anti-glaucoma drug, is currently used only systemically due to low solubility and permeation, which cause severe side effects. Developing topical medications with acetazolamide requires robust analytical methods for its detection in biological samples. In this context, this study aimed to develop a method to quantify acetazolamide in rabbit vitreous humor samples. The method involved a simple, fast, inexpensive, and environmentally friendly protein precipitation step for sample preparation, needing just 50 μL of sample and 200 μL of organic solvent, with adequate recovery. This was combined with high-performance liquid chromatography coupled to tandem mass spectrometry, enabling highly sensitive (LOQ of 5 ng/mL) quantification within only 5 min. The method proved to be selective, precise, and accurate, with well-fitted analytical curves, with no carryover, and no matrix effect impacting reliability. The method was successfully applied to analyze vitreous humor samples from rabbits in pharmacokinetic studies, monitoring drug release from intravitreal implants. Results showed a controlled release profile, with a maximum drug concentration (Cmax) of 426.01 ± 64.57 ng/mL, time to reach Cmax (Tmax) of 28 days, and area under the curve (AUC0-42 and AUC0-∞) of 7722.66 ± 1125.96 ng days/mL and 8998.11 ± 1311.92 ng days/mL, respectively. The device demonstrated significantly slower elimination, ensuring therapeutic levels for an extended period when compared to intravitreal injection.

31 Dec 2024·Journal of enzyme inhibition and medicinal chemistry

Acetazolamide and human carbonic anhydrases: retrospect, review and discussion of an intimate relationship

Review

Author: Tsikas, Dimitrios

Acetazolamide (AZM) is a strong pharmacological sulphonamide-type (R-SO₂-NH₂, pK_a 7.2) inhibitor of the activity of several carbonic anhydrase (CA) isoforms, notably of renal CA II (K_i, 12 nM) and CA IV (K_i, 74 nM). AZM is clinically used for about eighty years in various diseases including epilepsy and glaucoma. Pharmacological AZM increases temporarily the urinary excretion of bicarbonate (HCO₃^-) and sodium ions (Na⁺) and sustainably the urinary pH. AZM is excreted almost unchanged over several hours at high rates in the urine. Closely parallel concentrations of circulating and excretory AZM are observed upon administration of therapeutical doses of AZM. In a proof-of-principle study, we investigated the effects of the ingestion of a 250-mg AZM-containing tablet by a healthy volunteer on the urinary excretion of organic and inorganic substances over 5 h (range, 0, 0.5, 1, 1.5, 2, 3, 4, 5 h). Measured analytes included: AZM, amino acids and their metabolites such as guanidinoacetate, i.e. the precursor of creatine, of asymmetrically (ADMA) and symmetrically (SDMA) dimethylated arginine, nitrite (O = N-O^-, pK_a 3.4) and nitrate (O₂N-O^-, pK_a -1.37), the major metabolites of nitric oxide (NO), the C-H acidic malondialdehyde (MDA; (CHO)₂CH₂, pK_a 4.5), and creatinine for correction of analytes excretion. All analytes were measured by validated isotopologues using gas chromatography-mass spectrometry (GC-MS) methods. AZM excretion in the urine reached its maximum value after 2 h and was fairly stable for the next 3 h. Time series analysis by the ARIMA method was performed. AZM ingestion increased temporarily the urinary excretion of the amino acids Leu + Ile, nitrite and nitrate, decreased temporarily the urinary excretion of other amino acids. AZM decreased sustainably the urinary excretion of MDA, a biomarker of oxidative stress (i.e. lipid peroxidation). Whether this decrease is due to inhibition of the excretion of MDA or attenuation of oxidative stress by AZM is unknown. The acute and chronic effects of AZM on the urinary excretion of electrolytes and physiological substances reported in the literature are discussed in depth in the light of its extraordinary pharmacokinetics and pharmacodynamics. Tolerance development/drug resistance to AZM in chronic use and potential mechanisms are also addressed.

31 Dec 2024·Human Vaccines & Immunotherapeutics

Comprehensive insights into COVID-19 vaccine-associated multiple evanescent white dot syndrome (MEWDS): A systematic analysis of reported cases

Review

Author: Zhao, Mingyi ; Du, Ziye ; Zeng, Yuqin ; Shao, Chuhan

Considering the widespread use of COVID-19 vaccines as a preventive measure against the spread of the virus, it's necessary to direct attention to the adverse effects associated with vaccines in a limited group of populations. Multiple evanescent white dot syndrome (MEWDS) following COVID-19 vaccination is a rare adverse reaction associated with COVID-19 vaccines. In this systematic review, we collected 19 articles with 27 patients up to November 1, 2023, summarizing the basic information, clinical manifestations, examinations, treatments, and recoveries of the 27 patients. The 27 enrolled patients (6 males, 21 females) had a median age of 34.1 years (15-71 years old) and were mainly from 5 regions: Asia (8), the Mediterranean region (8), North America (7), Oceania (3) and Brazil (1). Symptoms occurred post-first dose in 9 patients, post-second dose in 14 (1 with symptoms after both), post-third dose in 1, and both post-second and booster doses in 1, while details on 2 cases were not disclosed. Treatments included tapered oral steroids (6), topical steroids (3), tapered prednisone with antiviral drugs and vitamins (1), and valacyclovir and acetazolamide (1), while 16 received no treatment. All patients experienced symptom improvement, and nearly all patients ultimately recovered. Moreover, we summarized possible hypotheses concerning the mechanism of COVID-19 vaccine-associated MEWDS. The findings provide insights into the clinical aspects of COVID-19 vaccine-associated MEWDS. More attention should be given to patients with vaccine-associated MEWDS, and necessary treatment should be provided to patients experiencing a substantial decline in visual acuity to improve their quality of life.

News (Medical) associated with Acetazolamide

03 Sep 2024

·www.businesswire.com

Obsidian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OBX-115 for the Treatment of Advanced Melanoma

CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to OBX-115 for the treatment of patients with unresectable or metastatic melanoma that is resistant to immune checkpoint inhibitor (ICI) therapy. OBX-115 is a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with membrane-bound IL15 (mbIL15) that is pharmacologically regulated using FDA-approved small molecule drug acetazolamide. This second FDA designation follows a July 2024 announcement of Fast Track designation for OBX-115. “RMAT designation for OBX-115 highlights the unmet need in ICI-resistant melanoma and OBX-115’s potential to provide patient-centric, transformative care in this setting,” said Parameswaran Hari, M.D., Chief Development Officer of Obsidian. “In an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, initial Phase 1 data showed that OBX-115 exhibited a favorable safety profile relative to what has been observed historically from IL2-dependent non-engineered TIL cell therapy, encouraging efficacy in patients with heavily pre-treated disease, and compatibility with non-surgical core needle biopsy tumor tissue procurement . We look forward to continued collaborative interaction with the FDA as we advance OBX-115 clinical development in both melanoma and non-small cell lung cancer (NSCLC).” Established under the 21st Century Cures Act, RMAT designation is a dedicated program that includes the benefits of Fast Track and Breakthrough Therapy designations and is designed to expedite the development and review processes for certain promising drug candidates, including cell therapies. An investigational cell therapy is eligible for RMAT designation if it meets the definition of regenerative medicine therapy, is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the therapy has the potential to address unmet medical needs for that disease. RMAT designation provides early and frequent interactions with the FDA, including intensive guidance on efficient drug development. Candidates receiving RMAT designation may also be eligible for Accelerated Approval and Priority Review. About OBX-115 Obsidian’s lead investigational cytoTIL15™ program, OBX-115, is a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15). OBX-115 has the potential to become a meaningful therapeutic option for patients with advanced or metastatic melanoma and other solid tumors by leveraging the expected benefits of mbIL15 and Obsidian’s proprietary, differentiated manufacturing process to enhance persistence, antitumor activity, and clinical safety of TIL cell therapy. Obsidian is investigating OBX-115 in a multicenter trial in patients with advanced melanoma or relapsed / refractory NSCLC ( NCT06060613 ). About Obsidian Therapeutics Obsidian Therapeutics, Inc. is a clinical-stage biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs. Obsidian is headquartered in Cambridge, MA. The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals. For more information, please visit www.obsidiantx.com and follow us on LinkedIn.

Cell TherapyImmunotherapyFast TrackPhase 1ASCO

03 Jun 2024

·www.biospace.com

Obsidian Therapeutics Announces Additional OBX-115 Safety and Efficacy Data in Oral Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

OBX-115 continues to demonstrate a positively differentiated safety pro to IL2-dependent non-engineered TIL cell therapy: no DLTs, no Grade 4 or higher non-hematologic TEAEs observed. OBX-115 efficacy pro in additional patients, including a 44% ORR with 2 CRs (n=9), and a 50% ORR in patients receiving cell dose >30 × 109 cells. Emerging survival and PFS data are promising, with no treatment- or disease-related mortality (OS 100%, median study follow-up of 29.5 weeks) and PFS of 75% at 24 weeks. CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Obsidian Therapeutics Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced updated data from the ongoing Phase 1 first-in-human, dose-escalation study of OBX-115, a novel engineered tumor-derived autologous T-cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15), in patients with immune checkpoint inhibitor (ICI)-resistant advanced or metastatic melanoma. These data were presented in an oral presentation delivered by Rodabe Amaria, M.D., professor of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center and principal investigator of the study, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The oral presentation for the single-center study (NCT05470283) included a 3-month incremental data update (relative to published abstract) on safety (N=10) and efficacy (n=9 per-protocol efficacy analysis set) for patients with advanced or metastatic melanoma. Summary of OBX-115 Safety and Efficacy Data (April 4, 2024 data cutoff): OBX-115 Exhibits Positively Differentiated Safety Pro to IL2-Dependent Non-Engineered TIL Cell Therapy: All 10 infused patients were alive at data cutoff (median study follow up of 29.5 weeks). No patient received care in the intensive care unit. No dose-limiting toxicities were observed at any dose level. No Grade 4 or higher non-hematologic treatment-emergent adverse events (TEAEs) were reported; 2 patients experienced limited Grade 3 non-hematologic TEAEs. No confirmed events of cytokine release syndrome, capillary leak syndrome, or immune effector cell-associated neurotoxicity syndrome were reported. OBX-115 Sustains Consistent Efficacy Profile, without IL2 Administration, in Patients with Substantially Pre-Treated Resistant/Refractory Disease: Patients had disease that was predominantly ICI primary-resistant, with a median of 3.5 (range, 1–6) lines of prior systemic therapy, including a median of 2 (1–3) lines of prior ICI therapy. 44% objective response rate (ORR), including 2 complete responses (CRs), using investigator-assessed RECIST 1.1 criteria across all doses (n=9 per-protocol efficacy analysis set). 50% ORR in patients who received OBX-115 dose of >30 × 109 cells (n=6). 100% disease control, defined as CR, PR, or ≥12-week duration of stable disease post OBX-115 infusion. Progression-free survival (PFS) was 75% at 24 weeks. Tumor burden reduction in all 9 patients, including several with tyrosine kinase inhibitor (TKI)-refractory disease and / or prior treated brain metastasis. Disease control and responses observed with both fresh and cryopreserved OBX-115 product. Additional OBX-115 Data Contributing to an Optimized Cell Therapy Product: Robust manufacturing process observed for OBX-115, including from tumor tissue obtained using core needle biopsy. Median manufactured OBX-115 dose (N=10): 100 × 109 cells. Translational data highlight that the OBX-115 infusion product is optimized for response and persistence: predominantly CD8+ cytotoxic T-cell population, effector memory phenotype, high proportion of CD8+CD39-CD69- (double-negative) “stem-like” progenitor cells and low levels of exhaustion markers. Dr. Amaria commented, “OBX-115 continues to demonstrate positive safety and efficacy data in additional patients, which is encouraging, given this is a heavily pre-treated patient population with advanced disease. Unfortunately, late-line systemic therapy options offer limited benefit, with ORR of approximately 10% and mPFS of approximately 2–3 months. It is exciting to see a potential new option emerge for these patients with a positively differentiated safety pro promising early activity achieved without IL2.” “We believe OBX-115 has the potential to advance the TIL cell therapy field in multiple ways, including enabling non-surgical tumor tissue procurement and abrogating the need for IL2. We are also exploring the ability to re-energize engrafted OBX-115 cells with acetazolamide re-dosing,” commented Parameswaran Hari, M.D., Chief Development Officer of Obsidian. “We look forward to continuing to build on this momentum and apply key learnings from the first-in-human Phase 1 study to our ongoing Phase 1/2 multicenter study, where we are continuing to explore these attributes and optimize the OBX-115 regimen in melanoma and non-small cell lung cancer.” Obsidian is actively enrolling patients with advanced or metastatic melanoma and non-small cell lung cancer (NSCLC) at multiple sites in its ongoing Phase 1/2 multicenter study. Additional details may be found at clinicaltrials.gov, using identifier: NCT06060613. About OBX-115 Obsidian’s lead investigational cytoTIL15™ program, OBX-115, is a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15). OBX-115 has the potential to become a meaningful therapeutic option for patients with advanced or metastatic melanoma and other solid tumors by leveraging the expected benefits of mbIL15 and Obsidian’s proprietary, differentiated manufacturing process to enhance persistence, antitumor activity, and clinical safety of TIL cell therapy. OBX-115 is being investigated in two ongoing clinical trials in advanced or metastatic melanoma and NSCLC (NCT05470283 and NCT06060613). About Obsidian Therapeutics Obsidian Therapeutics, Inc. is a clinical-stage biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs. Obsidian is headquartered in Cambridge, MA. The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals. For more information, please visit obsidiantx.com and follow us on LinkedIn.

Clinical ResultPhase 1Cell TherapyASCOImmunotherapy

04 Apr 2024

·www.pharmaceutical-technology.com

Obsidian raises $160.5m to advance TIL cell therapy programme

TIL therapy uses naturally occurring immune cells that detect and attack cancer cells. Image credit: Shutterstock/Christoph Burgstedt. Obsidian Therapeutics has raised $160.5m in a Series C financing round, with plans for the funds to be injected into the biotech’s tumour-infiltrating lymphocyte (TIL) cell therapy programme. Obsidian, already backed by Bristol Myers Squibb (BMS), added Novo Nordisk Foundation’s investment arm Novo Holdings to its arsenal of investors in this latest round. US investment firm Wellington Management led the oversubscribed Series C. The US biotech previously raised $115m in a Series B round in 2021. Obsidian’s lead asset is OBX-115 , which is part of its TIL programme. OBX-115 is a TIL cell therapy – which expands and enhances the patient’s own immune cells extracted from around and within the tumour itself. Unlike the emerging chimeric antigen receptor (CAR) T cell therapies , TILs already have multiple tumour target recognition. The T cell immunotherapy is in a Phase I clinical trial for the treatment of melanoma and a Phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC). In the melanoma trial (NCT05470283), which is being sponsored by the MD Anderson Cancer Centre, OBX-115 is being administered in combination with the diuretic acetazolamide. Data from the study will inform dose levels for a Phase II trial. The company reported an objective response rate of 50% and a complete response rate of 33% in topline data released in December 2023. See Also: Seaport emerges after $100m raise with ex-Karuna team at helm Pluri launches manufacturing division as cell therapy pipeline progresses The NSCLC trial (NCT06060613) is investigating OBX-115 as a monotherapy, with endpoints assessing the drug’s safety and efficacy in treating advanced solid tumours. Obsidian said the Series C proceeds will go towards clinical trial activities and manufacturing scale-up with a view to conducting pivotal trials. Obsidian has engineered OXB-115 such that it produces the membrane-bound interleukin 15 (IL-15). Interleukin-2 (IL-2) co-administration is usually needed with traditional TIL cell therapies to act as an immunostimulatory agent. Obsidian states that the membrane-bound IL-15 could widen patient access by reducing potential toxicities associated with high-dose IL-2. Vertex and BMS have seen the potential in Obsidian’s platform, both signing multi-year partnerships with the biotech to discover and develop new cell therapies. Last month, Iovance Biotherapeutics ’ Amtagvi (lifileucel) became the first TIL cell therapy to get regulatory backing in the US, winning a US Food and Drug Administration (FDA) accelerated approval. Obsidian’s OBX-115 will face competition from Iovance, with Amtagvi indicated for the treatment of metastatic or unresectable melanoma. Iovance has priced its immunotherapy at $515,000 in a market where there are currently no other FDA-approved cell therapies for the treatment of solid tumours. Amtagvi is forecast to generate sales of $846m by 2029, according to GlobalData’s Pharma Intelligence Centre. GlobalData is the parent company of Pharmaceutical Technology. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper Cell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead. By Cytiva Thematic By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy

Cell TherapyPhase 1ImmunotherapyClinical ResultGene Therapy

100 Deals associated with Acetazolamide

External Link

KEGG	Wiki	ATC	Drug Bank
D00218	Acetazolamide	S01EC01	DB00819

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pre-Eclampsia	JP	Sanwa Kagaku Kenkyusho Co., Ltd.	02 Jun 1994
Sleep Apnea Syndromes	JP	Sanwa Kagaku Kenkyusho Co., Ltd.	29 Mar 1988
Acidosis, Respiratory	JP	Sanwa Kagaku Kenkyusho Co., Ltd.	29 Mar 1955
Glaucoma	JP	Sanwa Kagaku Kenkyusho Co., Ltd.	29 Mar 1955
Meniere Disease	JP	Sanwa Kagaku Kenkyusho Co., Ltd.	29 Mar 1955
Premenstrual Syndrome	JP	Sanwa Kagaku Kenkyusho Co., Ltd.	29 Mar 1955
Endocrinology and Metabolic Disease	US	Teva Women's Health, Inc.	25 Jun 1954
Acute angle-closure glaucoma	US	Teva Branded Pharmaceutical Products R&D, Inc.	27 Jul 1953
Altitude Sickness	US	Teva Branded Pharmaceutical Products R&D, Inc.	27 Jul 1953
Edema	US	Teva Branded Pharmaceutical Products R&D, Inc.	27 Jul 1953
Epilepsy	US	Teva Branded Pharmaceutical Products R&D, Inc.	27 Jul 1953
Glaucoma, Open-Angle	US	Teva Branded Pharmaceutical Products R&D, Inc.	27 Jul 1953
Secondary glaucoma	US	Teva Branded Pharmaceutical Products R&D, Inc.	27 Jul 1953

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03505788 (ADVOR Trial \| Advor, CTgov)	Phase 4	Volume overload \| Metabolic Diseases \| Acute decompensated heart failure	519	placebo (Placebo)	yxblruoqsg(wzzrldzque) = orsyvdcexw byyqzihnmz (aflvhfyvgm, rxazkegsoy - fjdxxszclq) View more	-	28 Oct 2024
				Acetazolamide (Acetazolamide)	yxblruoqsg(wzzrldzque) = mdqzzsbfcg byyqzihnmz (aflvhfyvgm, bxbxvfjsli - cdvvtoxnee) View more
NCT04639193 (RESCUE-Combo, CTgov)	Phase 2	Sleep Apnea, Obstructive	20	Acetazolamide+Eszopiclone (Dual-Therapy)	fivkptswhr(sygllfkesu) = grluragufx onnicuchvr (qtaoyinvex, rgzpfygvun - ynokzzygsm) View more	-	02 May 2024
				Placebo+Acetazolamide+Eszopiclone (Placebo)	fivkptswhr(sygllfkesu) = egmrhpjgsd onnicuchvr (qtaoyinvex, xokfzztryo - xkofuonoqf) View more
NCT05023941 (Pubmed \| BMC Med)	Phase 4	Altitude Sickness venous blood gas \| complete blood count \| human cytokine antibody array ... View more	250	acetazolamide (RIPC)	qkoqcwqyck(fughkjrgzy) = myjteggpiu kouowtypcn (ravdkxpxav )	Positive	02 Jan 2024
				Acetazolamide	rkvwguhcag(yzzmogzsst) = gavodrcekc dgdjeukbfs (dlfedgugxl, 91)
CNS2023	Not Applicable	Status Epilepticus Second line	-	Acetazolamide (AZM)	bctmkevugp(yrcutvwcjx) = tqvhrpydgs wgvugpeetn (wqkxbhetnf )	-	01 Oct 2023
				Benzodiazepine - diazepam or clobazam	bctmkevugp(yrcutvwcjx) = dtoqgefcio wgvugpeetn (wqkxbhetnf )
NCT03505788 (ADVOR Trial, Pubmed)	Phase 4	Acute decompensated heart failure	519	Acetazolamide	njybqhpsts(irxysolbyw) = nwyenwpfke cxihiywohi (suagyndzdq )	-	25 Aug 2023
				Placebo	njybqhpsts(irxysolbyw) = lnwkgfpmxt cxihiywohi (suagyndzdq )
NCT03377049 (CTgov)	Phase 4	Aneurysm, Intracranial Berry, 1 \| Ischemia \| Vasospasm, Intracranial	11	Acetazolamide	stbohrcgte(aigyfbwbee) = gjraaoksgy dvebmekzoz (ghsulwukmb, mukhubcyex - nfpjojnxts) View more	-	27 Jul 2023
NCT03505788 (ADVOR, Pubmed)	Phase 4	Volume overload \| Acute decompensated heart failure	519	Acetazolamide	gpbmvptcwl(vviismfzfn) = pasrsiiimg vmcgvongrx (rryurkjczk ) View more	-	23 May 2023
ADVOR trial (ESC2023)	Not Applicable	-	519	Acetazolamide	lboqzbgcro(bomkrvmqbn) = kuughngzgg ysoklskjqc (lcswjmjour ) View more	-	21 May 2023
				Placebo	lboqzbgcro(bomkrvmqbn) = stywuyvmap ysoklskjqc (lcswjmjour ) View more
NCT02466074 (perfuseMS, CTgov)	Phase 2	Multiple Sclerosis	5	Acetazolamide (Acetazolamide)	pxyhlffwql(graobxujdy) = rjxwwnmpma jhwexqbrhv (qeiqfzruyw, jswlaahatu - rnlwqpcliy) View more	-	01 Mar 2023
				Placebo (Placebo)	mdmopalttn(zespieogcn) = irjtpyuizq jcfpjcvgad (dmhamfpogu, xonldnqovf - ruqwuacyvm) View more
NCT05290948 (Pubmed)	Phase 2	Retinal vein occlusion-related macular edema	54	IVB and OA combination therapy	agkvhuuqiw(cckmfcymba) = yzckibafpe bmakpcvrgp (kspndunnuo ) View more	-	02 Feb 2023
				IVB monotherapy	agkvhuuqiw(cckmfcymba) = kzfifswhpt bmakpcvrgp (kspndunnuo ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis